This study aims to elucidate the efficacy of TOL2506, a formulation of Leuprolide, in attenuating ovarian endocrine functionality in premenopausal women diagnosed with HR+, HER2-negative mammary carcinoma. Here, ERBB2 is linked to breast carcinoma.